contraindications for glp-1 agonists glp 1 Using information from the NPF Medical Board's publication in JAMA Dermatology GLP-1 Agonists - FAQ —
Description
Currently, 25% of adults in the United Kingdom are living with obesity and the rise in obesity has significantly increased the number of patients with T2DM [4,5,6]
We value your feedback.
However, it is critical to emphasize that the clinical data included in this meta-analysis do not directly demonstrate activation or inhibition of these pathways at the tissue or molecular level
TK wrote the first manuscript draft, which was critically revised by IA, AL and AT
Journal of Orthopaedic Translation
10.1002/med.20142 21 MohsinS.BaniyasM
